 |
市场调查报告书
商品编码
1767678
血管收缩素转化酵素(ACE) 抑制剂市场（按药物、适应症、给药途径、通路和地区划分）Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, By Indication, By Route of Administration, By Distribution Channel, and By Region |
||||||
价格
简介目录
血管收缩素转化酵素(ACE) 抑制剂市场规模预计在 2025 年为 90.003 亿美元，预计到 2032 年将达到 131.797 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 5.6%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025年的市场规模 | 90.3亿美元 |
| 效能数据 | 2020-2024 | 预测期 | 2025-2032 |
| 预测期：2025-2032年 | 5.60% | 2032年价值预测 | 131.797亿美元 |
血管收缩素转化酵素（ACE）抑制剂是一类主要用于治疗高血压和心臟衰竭的药物。它们透过阻断一种称为血管收缩素II的荷尔蒙的作用而起作用。血管收缩素II会使血管收缩并促进一种称为醛固酮的激素的分泌，这会导致体内液体和盐的储存。 ACE抑制剂透过阻断血管收缩素II的产生，减少体内滞留的液体量并降低血压，从而放鬆和扩张血管。常用的ACE抑制剂包括Lisinopril，Enalapril和Ramipril。副作用包括干咳，头晕和肾臟损伤。服用ACE抑制剂的人应定期检查以监测其肾功能和钾水平。 ACE抑制剂在减轻血管收缩素II的作用和帮助血管放鬆和扩张方面起着至关重要的作用，同时还能调节液体储存并大大有助于降低血压。
市场动态
全球血管收缩素转化酵素(ACE) 抑制剂市场的成长是由全球高血压和心臟病的高盛行率所推动的。人体会产生四种称为血管收缩素（an-gee-oh-ten-sin，罗马数字表示类型名称）的荷尔蒙。血管收缩素转换酶 (ACE) 将血管紧张素 I 转化为血管收缩素II，后者会产生各种生理效应。 ACE 抑制剂通常被建议使用，尤其用于治疗心血管疾病和高血压。 2019 年，超过 1,290 万名联邦医疗保险 (Medicare) D 部分用户（约占 D 部分受保受益人的 27%）使用了 ACE 抑制剂。 ACE 抑制剂确实会引起不良反应。大多数不良反应较为轻微，但也有少数情况危险，需要紧急医疗照护。
研究的主要特点
- 本报告对全球血管收缩素转化酵素(ACE) 抑制剂市场进行了详细分析，并提供了预测期 2025-2032 的市场规模（百万美元）和年复合成长率（CAGR%），假设基准年为 2024 年。
- 它还强调了各个领域的潜在商机，并解释了该市场的有吸引力的投资提案矩阵。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
- 全球血管收缩素转化酵素(ACE) 抑制剂市场的主要企业根据公司亮点、产品系列、关键亮点、性能和策略等参数进行分析。
- 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
- 全球血管收缩素转化酵素(ACE) 抑制剂市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
- 相关人员可以透过分析全球血管收缩素转化酵素(ACE) 抑制剂市场中使用的各种策略矩阵来促进决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
- 一致的机会图（COM）
第三章市场动态、法规与趋势分析
- 市场动态
- 驱动程式
- 高血压盛行率不断上升
- 不断成长的研发活动
- 提高心血管健康意识
- 限制因素
- 专利到期日
- 副作用和安全问题
- 副作用和安全问题
- 机会
- 驱动程式
- 提高心血管健康意识
- 个人化医疗
- 联合治疗
- 影响分析
- 监管情景
- 产品发布/核准
- PEST分析
- 波特分析
- 併购场景
4. 全球血管收缩素转化酵素(ACE) 抑制剂市场（依药物分类），2020 年至 2032 年
- 介绍
- Benazepril
- Perindopril
- 曲福普利
- Captopril
- Enalapril
- Lisinopril
- 其他（Ramipril等）
5. 全球血管收缩素转化酵素(ACE) 抑制剂市场（依适应症划分），2020 年至 2032 年
- 介绍
- 高血压
- 冠状动脉疾病
- 心臟衰竭
- 慢性肾臟病
- 硬皮症
- 其他（偏头痛等）
6. 全球血管收缩素转化酵素（ACE）抑制剂市场（依给药途径），2020-2032
- 介绍
- 口服
- 注射
7. 全球血管收缩素转化酵素（ACE）抑制剂市场（依通路划分），2020-2032
- 介绍
- 医院药房
- 零售药局
- 网路药局
8. 全球血管收缩素转化酵素（ACE）抑制剂市场（按地区），2020-2032
- 介绍
- 北美洲
- 美国
- 加拿大
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 东南亚国协
- 澳洲
- 韩国
- 其他亚太地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 中东和非洲
- 海湾合作委员会国家
- 以色列
- 北非
- 中部非洲
- 其他中东和非洲地区
第九章 竞争态势
- Novartis AG
- Pfizer Inc.
- Merck & Co.
- AstraZeneca
- Sanofi
- Boehringer Ingelheim
- GlaxoSmithKline
- Lupin Limited
- Torrent Pharmaceuticals Ltd.
- Reddy's Laboratories Ltd.
- Mylan
第 10 章 章节
- 调查方法
- 关于出版商
简介目录
Product Code: CMI2746
Angiotensin Converting Enzymes (ACE) Inhibitors Market is estimated to be valued at USD 9,000.3 Mn in 2025 and is expected to reach USD 13,179.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 9,000.3 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.60% | 2032 Value Projection: | USD 13,179.7 Mn |
Angiotensin converting enzymes (ACE) inhibitors are a type of medication used primarily in the treatment of high blood pressure and heart failure. They work by blocking the action of a hormone called angiotensin II. Angiotensin II causes blood vessels to constrict and promotes the release of another hormone called aldosterone, which leads to water and salt retention in the body. By inhibiting the production of angiotensin II, ACE inhibitors help to relax and widen the blood vessels, reduce the amount of water retained by the body, and therefore lower blood pressure. Commonly prescribed ACE inhibitors include lisinopril, enalapril, and ramipril. Side effects can include dry cough, dizziness, and kidney problems. It is important for individuals taking ACE inhibitors to have regular check-ups to monitor their kidney function and potassium levels. ACE inhibitors play a pivotal role in mitigating the effects of angiotensin II, aiding in the relaxation and widening of blood vessels while regulating fluid retention, thus contributing significantly to blood pressure reduction.
Market Dynamics
The global angiotensin converting enzymes (ACE) inhibitors market's growth is driven by the high prevalence of hypertension and heart disease globally. The body produces four distinct forms of the hormone angiotensin (an-gee-oh-ten-sin; the types' names are Roman numerals). Angiotensin I is converted to angiotensin II by ACE, which has a variety of bodily consequences. ACE inhibitors are often recommended, particularly for cardiovascular diseases and high blood pressure. An ACE inhibitor was given to over 12.9 million Medicare Part D participants in 2019 (or roughly 27% of all beneficiaries with Part D coverage). It is true that ACE inhibitors can cause negative effects. Most of them are mild, but a few are dangerous and require emergency medical attention.
Key features of the study
- This report provides in-depth analysis of the global angiotensin converting enzymes (ACE) inhibitors market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global angiotensin converting enzymes (ACE) inhibitors market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Novartis AG, Pfizer Inc., Merck & Co., AstraZeneca, Sanofi, Boehringer Ingelheim, GlaxoSmithKline, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Mylan and Other Prominent Players.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global angiotensin converting enzymes (ACE) inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global angiotensin converting enzymes (ACE) inhibitors market.
Market Segmentation
- By Drugs
- Benazepril
- Perindopril
- Trandfolapril
- Captopril
- Enalapril
- Lisinopril
- Others (Ramipril, etc.)
- By Indication
- Hypertension
- Coronary Artery Disease
- Heart Failure
- Chronic Kidney Disease
- Scleroderma
- Others (Migraine, etc.)
- By Route of Administration
- Oral
- Injectable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top companies in Global Angiotensin Converting Enzymes (ACE) Inhibitors Market
- Novartis AG
- Pfizer Inc.
- Merck & Co.
- AstraZeneca
- Sanofi
- Boehringer Ingelheim
- GlaxoSmithKline
- Lupin Limited
- Torrent Pharmaceuticals Ltd.
- Reddy's Laboratories Ltd.
- Mylan
- Other Prominent Players
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Drugs
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Indication
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Route of Administration
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Distribution Channel
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Rising prevalence of hypertension
- Growing Research and Development Activities
- Increasing Awareness of Cardiovascular Health
- Restraints
- Patent Expirations
- Side Effects and Safety Concerns
- Side Effects and Safety Concerns
- Opportunities
- Drivers
- Increasing Awareness of Cardiovascular Health
- Personalized medicine
- Combination therapies
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Benazepril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Perindopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Trandfolapril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Captopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Enalapril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Lisinopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Others (Ramipril, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
5. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Indication, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
- Coronary Artery Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
- Heart Failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
- Chronic Kidney Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
- Scleroderma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
- Others (Migraine, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
6. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Route of Administration, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
7. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
8. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (USD Mn)
- GCC
- Israel
- North Africa
- Central Africa
- Rest of Middle East & Africa
9. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Torrent Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
